Expertise in
23
conditions

Dr. Arthur R. Mabaquiao

Rheumatology
J. Lee MD Medical Corp. Inc.
1010 W La Veta Ave Ste 360, 
Orange, CA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
23
conditions
J. Lee MD Medical Corp. Inc.
1010 W La Veta Ave Ste 360, 
Orange, CA 

Overview

Arthur Mabaquiao is a Rheumatologist practicing medicine in Orange, California.

Dr. Mabaquiao is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Microscopic Polyangiitis, Sjogren Syndrome, and Necrotizing Vasculitis.

He is actively involved in clinical research, participating in 8 clinical trials. Dr. Mabaquiao is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in CA

Hospital Affiliations

Grossmont Hospital
Sharp Coronado Hospital And Hlthcr Ctr
Sharp Chula Vista Medical Center
El Centro Regional Medical Center
Sharp Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
Moda Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

J. Lee MD Medical Corp. Inc.
1010 W La Veta Ave Ste 360, Orange, CA 92868
Other Locations
Genalyte Distributed Laboratory #3
300 S Pierce St Ste 203, El Cajon, CA 92020

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: November 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: June 11, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Expertise in
13
conditions
Dr. Daniel E. Furst
Rheumatology
Expertise in
13
conditions
Dr. Daniel E. Furst
Rheumatology
Referral may be required
Before you request

Daniel Furst MD A Professional Corp.

575 E Hardy St Ste 321, 
Inglewood, CA 
 (29.2 miles away)
818-561-9989
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Furst is a Rheumatologist practicing medicine in Inglewood, California. Dr. Furst is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Scleroderma, Rheumatoid Arthritis (RA), and Arthritis. Dr. Furst is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required
2020 Santa Monica Boulevard, Suite 540, 
Santa Monica, CA 
 (38.4 miles away)
310-582-6350
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tanaz Kermani is a Rheumatologist practicing medicine in Santa Monica, California. Dr. Kermani is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Giant Cell Arteritis (GCA), Temporal Arteritis, Vasculitis, and Takayasu Arteritis. Dr. Kermani is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required
Before you request

Cedars-Sinai Rheumatology-Los Angeles

8723 Alden Dr Ste 250, 
Los Angeles, CA 
 (34.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Wallace is a Rheumatologist practicing medicine in Los Angeles, California. Dr. Wallace is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Sjogren Syndrome, and Rheumatoid Arthritis (RA). Dr. Wallace is currently accepting new patients.

Frequently Asked Questions about Dr. Arthur R. Mabaquiao

How do I make an appointment with Dr. Arthur R. Mabaquiao?

You can book an appointment with Dr. Arthur R. Mabaquiao by calling their office at 714-245-0492. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Arthur R. Mabaquiao a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Arthur R. Mabaquiao is classified as an Distinguished expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Arthur R. Mabaquiao specialize in?

While Dr. Arthur R. Mabaquiao is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Microscopic Polyangiitis, and Sjogren Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Arthur R. Mabaquiao accept my insurance?

Dr. Arthur R. Mabaquiao accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 714-245-0492 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mabaquiao's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile